Last reviewed · How we verify
NCT04853095: PerFix
Effect of Peritoneal Fixation on Lymphocele Formation
NA trial testing Peritoneal fixation (PerFix) in Prostate Cancer in 260 participants. Completed in 1 January 2022.
31 December 2021
Quick facts
| Lead sponsor | University Hospital Olomouc |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 260 |
| Start date | 1 December 2019 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Peritoneal fixation (PerFix)
- Standard of care
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Lymphocele After Surgical Procedure — all drugs for Lymphocele After Surgical Procedure →
Sponsor
University Hospital Olomouc
Who can join
18 and older, male only, with Prostate Cancer or Lymphocele After Surgical Procedure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PerFix Trial aims to compare the use of peritoneal fixation technique to standard of care (no fixation) during robot-assisted radical prostatectomy with extended pelvic lymph node dissection (RARP + eLND) for the prevention of symptomatic and radiologic lymphocele formation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04853095
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other University Hospital Olomouc trials
Trials by the same sponsor.
- NCT06981026 — The Effectiveness of Telemedicine Monitoring Prehabilitation in Prostate Cancer Patients Undergoing Radical Prostatectom · NA · not yet recruiting
- NCT07360886 — Early Detection of Selected Neuropathologies in Motor Vehicle Drivers · recruiting
- NCT07356076 — The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases · recruiting
- NCT07075679 — Screening Mammography: Single Reading by One Radiologist With AI vs. Double Reading by Two Radiologists (AI-BCSQ) · NA · recruiting
- NCT06050057 — Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04853095 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Olomouc
- Last refreshed: 16 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04853095.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing